On May 19, 2026, the 2026 Future Medical & Pharmaceutical Top 100 Conference hosted by Vcbeat was grandly held. Hangzhou NEUREAL Technology Co., Ltd. (hereinafter referred to as NEUREAL), a benchmark enterprise in digital healthcare and BCI, was invited to attend. Dr. Ma Ning, Chief Brain Science Expert, delivered a keynote speech at the BCI Industry Innovation and Investment Forum. On May 21, the company won two major industry awards: the Top 100 Innovative Devices and Intelligent Manufacturing List and the Top 50 Most Investable Enterprises, demonstrating its technical strength and industry influence in the BCI field.
NEUREAL: Deepening BCI Expertise, Building a Benchmark for Specialized, Refined, Distinctive, and Innovative Enterprises
As a national-level "Little Giant" specialized, refined, distinctive, and innovative enterprise, NEUREAL focuses on chronic brain disorders and psychiatric rehabilitation. Its self-developed BCI+X precision diagnosis and treatment platform for brain disorders constructs a complete technical system of "precise neural signal induction—target localization—dynamic closed-loop intervention," breaking the limitations of traditional unidirectional rehabilitation output. It provides precise digital intelligence solutions for brain disorders such as stroke, cognitive impairment, ADHD, depression, and anxiety disorder. Currently, core products have been deployed in over 1,000 hospitals nationwide, serving nearly ten million patients, making it a representative enterprise in the BCI and digital healthcare fields.
Cutting-edge Insights: Psychiatric Care Moving from Empirical Medicine to Precision Medicine
The BCI Industry Innovation and Investment Forum at the 2026 Future Medical & Pharmaceutical Top 100 Conference gathered top experts, clinical authorities, leading enterprises, and industrial investors from domestic BCI, neuroscience, and digital healthcare fields. It is a high-level academic exchange and industry alignment event with significant influence, focusing on clinical translation of BCI technology, industrial implementation paths, and development trends. It deeply analyzes new opportunities and directions in the sector, building an authoritative communication platform for the innovative development of China's brain science medical industry.
In his speech, Dr. Ma Ning pointed out that current global psychiatric care still relies on empirical behavioral observation-based diagnosis and treatment formed a century ago, suffering from low efficiency and strong subjectivity, making individualized precision intervention difficult. With the convergence of BCI, VR, and AI technologies, the industry urgently needs to shift towards a mechanism-oriented precision medicine paradigm. The key to this transformation lies in acquiring high-quality neural signal sources and inducing the optimal brain-behavior state for individuals.
▲ Dr. Ma Ning, Chief Brain Science Expert at NEUREAL
As a pioneer in domestic VR-BCI rehabilitation, NEUREAL has built a precise closed-loop rehabilitation path of "signal monitoring-intelligent intervention-dynamic adaptation-neural remodeling" relying on its self-developed whole-brain embodied simulation model. Currently, the company's technical solutions have been implemented in over 1,000 hospitals nationwide. Among them, the autism AI screening project shortens the traditional 20-30 minute manual assessment process to 5 minutes, with accuracy significantly superior to traditional manual assessments, providing an efficient and objective new tool for early screening and diagnosis of clinical psychiatric disorders.
Dr. Ma Ning stated that NEUREAL will continue to deepen the application of BCI+X technology in mental health, providing individualized and quantifiable precision diagnosis and treatment plans for more patients with neurodevelopmental and psychiatric disorders through precise neural signal induction technology and a complete closed-loop diagnosis and treatment system.
Strength Crowned: Dual Honors Reflecting Industry Recognition
At this conference, NEUREAL won two major industry awards—the Top 100 Innovative Devices and Intelligent Manufacturing List and the Top 50 Most Investable Enterprises—thanks to its years of technical accumulation in the BCI track, continuous breakthroughs in scientific research innovation, increasingly mature commercialization layout, and impressive implementation results in digital healthcare. This once again demonstrates its strong comprehensive development capabilities to the entire industry.
▲ Top 100 Innovative Devices and Intelligent Manufacturing List
Being selected for the Top 100 Innovative Devices and Intelligent Manufacturing List fully reflects the industry's affirmation of NEUREAL's hardcore technical strength in non-invasive BCI medical device R&D and intelligent rehabilitation device innovation. Being rated among the Top 50 Most Investable Enterprises represents the high confidence of capital markets and industrial investment circles in NEUREAL's future development prospects, growth potential in the track, and commercial monetization capabilities.
▲ Top 50 Most Investable Enterprises
These honors are not only high recognition of NEUREAL's long-term commitment to technological innovation, deep engagement in clinical scenarios, and steady advancement of industrial layout, but also mark the further consolidation of its benchmark status in the BCI and digital healthcare tracks. In the future, NEUREAL will lead the industry's standardized development with its benchmark power, helping China's BCI industry enter a new stage of development.
Unchanged Mission: Empowering a New Paradigm for Precision Diagnosis and Treatment in China's BCI Sector
From clinical implementation to industry voice, from technological innovation to honor crowning, NEUREAL has always adhered to the mission of "improving human brain health through technology," continuously driving the innovation of BCI precision diagnosis and treatment models. In the future, NEUREAL will continue to deepen BCI+X technology, strengthen cooperation with clinical institutions, accelerate the R&D and implementation of digital therapeutics products, bring scientific and efficient diagnosis and treatment solutions to more patients, and support the high-quality development of China's brain science medical industry.
